Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007
Date:11/13/2007

Company Provides Update on Oncology Pipeline Progress

SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced financial results for the three and nine months ended September 30, 2007. For the three months ended September 30, 2007, the Company posted revenues of $7.6 million and a net loss of $4.8 million. For the nine months ended September 30, 2007, revenues were $27.1 million and the net loss was $9.9 million. Cash, cash equivalents and short-term investments totaled $21.4 million at September 30, 2007 compared to $33.9 million at December 31, 2006.

Pipeline Update

* The IND submission for SGX523, the Company's lead MET inhibitor, is

expected to be made prior to year end, with Phase 1 clinical trials

anticipated to begin in early 2008. The Company is also moving

forward a number of other MET inhibitors with differing profiles to

SGX523 to further broaden the scope of the program.

* SGX393, a BCR-ABL inhibitor the Company is developing for the

relapsed/refractory Chronic Myelogenous Leukemia (CML) patient

population, is in formal toxicology studies and an IND submission is

targeted for the first half of 2008. Initial clinical studies are

planned to focus on patients with the most clinically challenging

CML mutation, known as the T315I mutant.

* Other BCR-ABL inhibitors, with potential to target the front-line

patient population, are undergoing preclinical studies in

collaboration with Novartis.

"We are excited about the progress of our pipeline candidates this quarter, particularly in our M
'/>"/>

SOURCE SGX Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, survivor of a severe 1987 ... he recalled that his equipment was set up to depict the newly poured concrete. With ... bed. , The photo speaks for itself. Chatfield is also a highly praised safety and ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... blog post that encourages the understanding and treatment of ankle sprains. A common ... in-home remedies. This can be dangerous if the condition augments and causes more ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's ... on Thursday, September 17th at Ford Field in Detroit and the second match will ...
(Date:7/31/2015)... ... 31, 2015 , ... everMaya ( http://evermaya.com/ ), a Fashion ... will be named for Madeline Stuart, an 18-year-old model from Brisbane, Australia. Ms. ... with Down syndrome, gracing the front pages of publications across the world. everMaya ...
(Date:7/31/2015)... Detroit, MI (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable ... The U.S. Women's National Soccer Team will face the Australia Women's National Team in conjunction ... by a score of 5-2. Carli Lloyd from the USA team was awarded the ...
Breaking Medicine News(10 mins):Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... 26 Researchers at Wayne State University ... that may one day lead to new treatments.Prostate cancer, ... affects one in six men. In 2008, nearly ... nearly 186,000 were newly diagnosed, and approximately 28,000 died ...
... interactive pediatric healthcare education and resources for hospitals, physicians, and ... ... Wilmington, DE (PRWEB) March 26, 2009 -- Emmi Solutions ... and information programs, and KidsHealth ®, the largest provider ...
... Venture Capital Community to Drive Innovation through Investment Opportunities ... 26 The 510(k) program is under siege from ... complained in a letter to Congress that CDRH management ... 510(k)s. They followed that complaint to Congress with ...
... 26, 2009 Nearly 90 percent of the 700,000 strokes ... a blockage of blood vessels supplying the brain, known ... Catheterization and Cardiovascular Interventions , the official journal of ... solid evidence of the effectiveness of catheter-based therapy (CBT) ...
... a Mayo Clinic study show that a simple, noninvasive finger ... such as a heart attack or stroke, for people who ... study will be presented Tuesday, March 31, 2009 at 11:30 ... Annual Scientific Session in Orlando (0917-7).The noninvasive finger test device, ...
... Sure There,s a Rollover Bar Above Your Head , ... Bloomington, MN ... buyers of previously owned commercial zero-radius-turn (ZRT) mowers to check that each ... to a roll bar on a race car, an overhead ROPS and ...
Cached Medicine News:Health News:Wayne State University Scientists ID New Biomarker for Prostate Cancer 2Health News:Emmi + KidsHealth = Prescription for Informed and Involved Patients 2Health News:Emmi + KidsHealth = Prescription for Informed and Involved Patients 3Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 2Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 3Health News:FDA Fireside Chat @ The 8th Annual MedTech Investing Conference May 6-7, 2009 4Health News:Individualized stroke treatment available for patients, though underutilized 2Health News:Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack 2Health News:Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack 3Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 2Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 3Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 4Health News:Safety Alert for Buyers of Used Commercial Zero Turn Mowers 5
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015 ... research report with market overview, trends, DRO ... porter analysis, recent developments, competitive scenario and ... Industry Insight: Biosensors Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... Analysis of SPIRIT II and SPIRIT III Data Confirms Patients ... Death, a Heart Attack or a ... TAXUS(R) at Two Years, WASHINGTON, Oct. 13 Data ... randomized clinical,trials demonstrated that the XIENCE V(TM) Everolimus Eluting Coronary ...
... Class, of Stent with Polyzene(R)-F Surface ... for Long-Term,Dual Antiplatelet Therapy, WASHINGTON, ... today,s,"Innovative Devices and Futuristic Therapies" session ... (TCT) scientific,symposium, sponsored by the Cardiovascular ...
Cached Medicine Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 2Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 3Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 4Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 512-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: